Please Wait.....
Report
Global Oncology Biosimilars Market
Market Research Report I 2025-12-31 I 173 Pages I BCC Research
Description
Report Scope
The report examines and segments the global oncology biosimilars market by indication, drug class, route of administration and distribution channel. It also provides insights into key emerging trends and potential growth drivers. The study focuses on indications such as breast, lung and blood cancers and others. By drug class, it focuses on granulocyte colony-stimulating factors, monoclonal antibodies, hematopoietic agents and others. By route of administration, the focus is on intravenous, subcutaneous and others. The report also examines hospital, retail and online pharmacies and others by distribution channel.
Included is a regional analysis of North America, Europe, Asia-Pacific, South America and the Middle East and Africa that evaluates the impact of AI adoption on the oncology biosimilars industry and market dynamics, including drivers, challenges and emerging trends, while highlighting product and performance enhancement innovations. The study concludes with an analysis of major companies in the market and their offerings.
It includes global revenue ($ million) for the base year 2024, estimated for 2025 and data for the forecast period 2026 through 2030.
Report Includes
- 140 data tables and 40 additional tables
- In-depth analysis of the global market for oncology biosimilar drugs
- Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by disease indication (cancer type), drug class, route of administration, distribution channel and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
- Impact analysis of the U.S. tariffs on the market for biologics used in cancer treatment and supportive care
- Insights derived from Porter's Five Forces model, as well as global supply chain analyses
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Samsung Bioepis, Sandoz Group AG, Celltrion Inc., Amgen Inc., and Biocon Biologics Ltd.
Executive Summary
Summary:
The global market for oncology biosimilars is estimated to grow from $9.6 billion in 2025 and projected to reach $17.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2030.
Oncology biosimilars leverage advanced algorithms and machine learning to optimize the entire clinical R&D process. These technologies streamline trial design, patient recruitment, monitoring and data analysis, enabling faster and more accurate decision-making. By reducing operational inefficiencies and timelines, oncology biosimilars development benefits from real-time, data-driven insights that support precision medicine approaches. Integrating tools such as predictive analytics, natural language processing and adaptive monitoring ensures that oncology biosimilar trials are not only more efficient but also better aligned with the complexities of cancer care, ultimately accelerating the availability of cost-effective biologic alternatives. The global oncology biosimilars market was valued at $REDACTED in 2024 and is expected to reach $REDACTED by the end of 2030. The market is expected to grow at a CAGR of REDACTED% during the forecast period.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Current Market Overview
Future Outlook
Analysis of Macroeconomic Factors
Impact of U.S. Tariffs on the Market
Impact of the Ukraine-Russia War
Economic Growth and Development
Demographic Shifts
Healthcare Expenditure Trends
Inflation and Currency Fluctuations
Porter's Five Forces Analysis
Chapter 3 Market Dynamics
Overview
Market Drivers
Surge in Global Cancer Incidence
Expiration of Blockbuster Biologic Patents
Need for Cost-Effective Cancer Therapies
Demand for Targeted and Supportive Oncology Treatments
Market Restraints
Regulatory Complexity and Approval Hurdles
Patent Challenges and Legal Barriers
Pharmacy Benefit Manager Practices
Market Opportunities
Expansion into Emerging Markets
Development of Novel Biosimilar Combinations and Specialty Formulations
Chapter 4 Regulatory Landscape
Regulatory Framework
U.S.
Europe
India
Australia
Japan
Chapter 5 Emerging Technologies and New Developments
Overview
Emerging Technologies
Advanced Cell Line Engineering
Artificial Intelligence and Machine Learning in Biosimilar Development
Gene Editing and Synthetic Biology Approaches
Modular and Single-Use Bioreactors
Patent Analysis
Key Takeaways
Patents, by Year
Patents, by Leading Jurisdiction
Patents, by Leading Inventor
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Oncology Biosimilars Market, by Indication
Key Takeaways
Breast Cancer
Lung Cancer
Blood Cancer
Others
Global Oncology Biosimilars Market, by Drug Class
Key Takeaways
Granulocyte Colony-Stimulating Factor
Monoclonal Antibodies
Hematopoietic Agents
Others
Global Oncology Biosimilars Market, by Route of Administration
Key Takeaways
Intravenous
Subcutaneous
Others RoA
Global Oncology Biosimilars Market, by Distribution Channel
Key Takeaways
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Geographic Breakdown
Global Oncology Biosimilars Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Competitive Intelligence
Industry Structure
Company Share Analysis for Oncology Biosimilars Market
Strategic Analysis
Chapter 8 Sustainability in the Oncology Biosimilars Market: ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives of the Oncology Biosimilars Industry
Concluding Remarks
Chapter 9 Appendix
Methodology
Abbreviations
Company Profiles
ACCORD HEALTHCARE
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
APOTEX INC.
BIOCAD
BIOCON BIOLOGICS LTD.
CELLTRION INC.
FRESENIUS KABI AG
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.
Emerging Start-ups/Market Disruptors
List of Tables
Summary Table : Global Market for Oncology Biosimilars, by Region, Through 2030
Table 1 : Real GDP Growth, by Country, 2022-2025
Table 2 : Pricing Analysis for Oncology WAC and ASP, 2024
Table 3 : Patents Granted for Oncology Biosimilars, by Year, 2022-2025
Table 4 : Patents Granted for Oncology Biosimilars, by Top Jurisdiction, 2022-2025
Table 5 : Patents Granted for Oncology Biosimilars, by Top Inventor, 2022-2025
Table 6 : Global Market for Oncology Biosimilars, by Indication, Through 2030
Table 7 : Global Market for Breast Cancer, by Region, Through 2030
Table 8 : Global Market for Lung Cancer, by Region, Through 2030
Table 9 : Global Market for Blood Cancer, by Region, Through 2030
Table 10 : Global Market for Other Types of Cancer, by Region, Through 2030
Table 11 : Global Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 12 : Global Market for Granulocyte Colony-Stimulating Factor, by Region, Through 2030
Table 13 : Global Market for Monoclonal Antibodies, by Region, Through 2030
Table 14 : Global Market for Hematopoietic Agents, by Region, Through 2030
Table 15 : Global Market for Other Drug Classes, by Region, Through 2030
Table 16 : Global Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 17 : Global Market for Intravenous Route of Administration, by Region, Through 2030
Table 18 : Global Market for Subcutaneous Route of Administration, by Region, Through 2030
Table 19 : Global Market for Other Routes of Administration, by Region, Through 2030
Table 20 : Global Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 21 : Global Market for Hospital Pharmacies for Oncology Biosimilars, by Region, Through 2030
Table 22 : Global Market for Retail Pharmacies for Oncology Biosimilars, by Region, Through 2030
Table 23 : Global Market for Online Pharmacies for Oncology Biosimilars, by Region, Through 2030
Table 24 : Global Market for Other Distribution Channels for Oncology Biosimilars, by Region, Through 2030
Table 25 : Global Market for Oncology Biosimilars, by Region, Through 2030
Table 26 : North American Market for Oncology Biosimilars, by Indication, Through 2030
Table 27 : North American Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 28 : North American Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 29 : North American Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 30 : North American Market for Oncology Biosimilars, by Country, Through 2030
Table 31 : U.S. Market for Oncology Biosimilars, by Indication, Through 2030
Table 32 : U.S. Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 33 : U.S. Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 34 : U.S. Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 35 : Canadian Market for Oncology Biosimilars, by Indication, Through 2030
Table 36 : Canadian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 37 : Canadian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 38 : Canadian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 39 : Mexican Market for Oncology Biosimilars, by Indication, Through 2030
Table 40 : Mexican Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 41 : Mexican Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 42 : Mexican Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 43 : European Market for Oncology Biosimilars, by Indication, Through 2030
Table 44 : European Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 45 : European Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 46 : European Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 47 : European Market for Oncology Biosimilars, by Country, Through 2030
Table 48 : German Market for Oncology Biosimilars, by Indication, Through 2030
Table 49 : German Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 50 : German Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 51 : German Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 52 : U.K. Market for Oncology Biosimilars, by Indication, Through 2030
Table 53 : U.K. Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 54 : U.K. Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 55 : U.K. Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 56 : French Market for Oncology Biosimilars, by Indication, Through 2030
Table 57 : French Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 58 : French Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 59 : French Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 60 : Italian Market for Oncology Biosimilars, by Indication, Through 2030
Table 61 : Italian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 62 : Italian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 63 : Italian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 64 : Spanish Market for Oncology Biosimilars, by Indication, Through 2030
Table 65 : Spanish Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 66 : Spanish Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 67 : Spanish Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 68 : Rest of Europe Market for Oncology Biosimilars, by Indication, Through 2030
Table 69 : Rest of Europe Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 70 : Rest of Europe Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 71 : Rest of Europe Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 72 : Asia-Pacific Market for Oncology Biosimilars, by Indication, Through 2030
Table 73 : Asia-Pacific Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 74 : Asia-Pacific Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 75 : Asia-Pacific Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 76 : Asia-Pacific Market for Oncology Biosimilars, by Country, Through 2030
Table 77 : Chinese Market for Oncology Biosimilars, by Indication, Through 2030
Table 78 : Chinese Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 79 : Chinese Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 80 : Chinese Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 81 : Japanese Market for Oncology Biosimilars, by Indication, Through 2030
Table 82 : Japanese Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 83 : Japanese Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 84 : Japanese Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 85 : Indian Market for Oncology Biosimilars, by Indication, Through 2030
Table 86 : Indian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 87 : Indian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 88 : Indian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 89 : South Korean Market for Oncology Biosimilars, by Indication, Through 2030
Table 90 : South Korean Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 91 : South Korean Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 92 : South Korean Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 93 : Australian Market for Oncology Biosimilars, by Indication, Through 2030
Table 94 : Australian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 95 : Australian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 96 : Australian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 97 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Indication, Through 2030
Table 98 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 99 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 100 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 101 : MEA Market for Oncology Biosimilars, by Indication, Through 2030
Table 102 : MEA Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 103 : MEA Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 104 : MEA Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 105 : MEA Market for Oncology Biosimilars, by Sub-region, Through 2030
Table 106 : Middle East Market for Oncology Biosimilars, by Indication, Through 2030
Table 107 : Middle East Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 108 : Middle East Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 109 : Middle East Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 110 : African Market for Oncology Biosimilars, by Indication, Through 2030
Table 111 : African Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 112 : African Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 113 : African Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 114 : South American Market for Oncology Biosimilars, by Indication, Through 2030
Table 115 : South American Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 116 : South American Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 117 : South American Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 118 : South American Market for Oncology Biosimilars, by Country, Through 2030
Table 119 : Brazilian Market for Oncology Biosimilars, by Indication, Through 2030
Table 120 : Brazilian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 121 : Brazilian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 122 : Brazilian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 123 : Argentine Market for Oncology Biosimilars, by Indication, Through 2030
Table 124 : Argentine Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 125 : Argentine Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 126 : Argentine Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 127 : Rest of South America Market for Oncology Biosimilars, by Indication, Through 2030
Table 128 : Rest of South America Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 129 : Rest of South America Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 130 : Rest of South America Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 131 : Strategic Initiatives for Oncology Biosimilars Market, 2024-2025
Table 132 : Abbreviations Used in the Global Oncology Biosimilars Market
Table 133 : Accord Healthcare: Company Snapshot
Table 134 : Accord Healthcare: Product Portfolio
Table 135 : Alvotech: Company Snapshot
Table 136 : Alvotech: Financial Performance, FY 2023 and 2024
Table 137 : Alvotech: Product Portfolio
Table 138 : Alvotech: News/Key Developments, 2024-2025
Table 139 : Amgen Inc.: Company Snapshot
Table 140 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 141 : Amgen Inc.: Product Portfolio
Table 142 : Amneal Pharmaceuticals LLC.: Company Snapshot
Table 143 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024
Table 144 : Amneal Pharmaceuticals LLC.: Product Portfolio
Table 145 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023-2025
Table 146 : Apotex Inc.: Company Snapshot
Table 147 : Apotex Inc.: Product Portfolio
Table 148 : Biocad: Company Snapshot
Table 149 : Biocad: Product Portfolio
Table 150 : Biocon Biologics Ltd.: Company Snapshot
Table 151 : Biocon Biologics Ltd.: Financial Performance, FY 2023 and 2024
Table 152 : Biocon Biologics Ltd.: Product Portfolio
Table 153 : Biocon Biologics Ltd.: News/Key Developments, 2023-2025
Table 154 : Celltrion Inc.: Company Snapshot
Table 155 : Celltrion Inc.: Financial Performance, FY 2023 and 2024
Table 156 : Celltrion Inc.: Product Portfolio
Table 157 : Celltrion Inc.: News/Key Developments, 2025
Table 158 : Fresenius Kabi AG: Company Snapshot
Table 159 : Fresenius Kabi AG: Product Portfolio
Table 160 : Fresenius Kabi AG: News/Key Developments, 2023-2025
Table 161 : Pfizer Inc.: Company Snapshot
Table 162 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 163 : Pfizer Inc.: Product Portfolio
Table 164 : Pfizer Inc.: News/Key Developments, 2023-2025
Table 165 : Samsung Bioepis: Company Snapshot
Table 166 : Samsung Bioepis: Product Portfolio
Table 167 : Samsung Bioepis: News/Key Developments, 2024
Table 168 : Sandoz Group AG: Company Snapshot
Table 169 : Sandoz Group AG: Financial Performance, FY 2023 and 2024
Table 170 : Sandoz Group AG: Product Portfolio
Table 171 : Sandoz Group AG: News/Key Developments, 2024-2025
Table 172 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 173 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 174 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 175 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023-2025
Table 176 : Viatris Inc.: Company Snapshot
Table 177 : Viatris Inc.: Financial Performance, FY 2023 and 2024
Table 178 : Viatris Inc.: Product Portfolio
Table 179 : List of a Few Emerging Startups
List of Figures
Summary Figure : Global Market Shares for Oncology Biosimilars, by Region, 2024
Figure 1 : Porter's Five Forces Analysis - Oncology Biosimilars Market
Figure 2 : Global Market Dynamics of Oncology Biosimilars
Figure 3 : Global Market Shares for Oncology Biosimilars, by Indication, 2024
Figure 4 : Global Market Shares for Breast Cancer, by Region, 2024
Figure 5 : Global Market Shares for Lung Cancer, by Region, 2024
Figure 6 : Global Market Shares for Blood Cancer, by Region, 2024
Figure 7 : Global Market Shares for Other Types of Cancer, by Region, 2024
Figure 8 : Global Market Shares for Oncology Biosimilars, by Drug Class, 2024
Figure 9 : Global Market Shares for Granulocyte Colony-Stimulating Factor, by Region, 2024
Figure 10 : Global Market Shares for Monoclonal Antibodies, by Region, 2024
Figure 11 : Global Market Shares for Hematopoietic Agents, by Region, 2024
Figure 12 : Global Market Shares for Other Drug Classes, by Region, 2024
Figure 13 : Global Market Shares for Oncology Biosimilars, by Route of Administration, 2024
Figure 14 : Global Market Shares for Intravenous Route of Administration, by Region, 2024
Figure 15 : Global Market Shares for Subcutaneous Route of Administration, by Region, 2024
Figure 16 : Global Market Shares for Other Routes of Administration, by Region, 2024
Figure 17 : Global Market Shares for Oncology Biosimilars, by Distribution Channel, 2024
Figure 18 : Global Market Shares for Hospital Pharmacies for Oncology Biosimilars, by Region, 2024
Figure 19 : Global Market Shares for Retail Pharmacies for Oncology Biosimilars, by Region, 2024
Figure 20 : Global Market Shares for Online Pharmacies for Oncology Biosimilars, by Region, 2024
Figure 21 : Global Market Shares for Other Distribution Channels for Oncology Biosimilars, by Region, 2024
Figure 22 : Global Market Shares for Oncology Biosimilars, by Region, 2024
Figure 23 : North American Market Shares for Oncology Biosimilars, by Country, 2024
Figure 24 : European Market Shares for Oncology Biosimilars, by Country, 2024
Figure 25 : Asia-Pacific Market Shares for Oncology Biosimilars, by Country, 2024
Figure 26 : MEA Market Shares for Oncology Biosimilars, by Sub-region, 2024
Figure 27 : South American Market Shares for Oncology Biosimilars, by Country, 2024
Figure 28 : Global Market Share Analysis for Oncology Biosimilars, by Major Companies, 2024
Figure 29 : Alvotech: Revenue Share, by Country/Region, FY 2024
Figure 30 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 32 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024
Figure 33 : Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 34 : Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 35 : Celltrion Inc.: Revenue Share, by Business Unit, FY 2024
Figure 36 : Celltrion Inc.: Revenue Share, by Country/Region, FY 2024
Figure 37 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 38 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 39 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2024
Figure 40 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2024
Figure 41 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 42 : Viatris Inc.: Revenue Share, by Business Unit, FY 2024
Figure 43 : Viatris Inc.: Revenue Share, by Country/Region, FY 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security